Citigroup
DMAC icon

Citigroup’s DiaMedica Therapeutics DMAC Stock Holding History

Citigroup’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
17,272
+15,376
+811% +$94.5K ﹤0.01% 4575
2026
Q1 		$12.8K Buy
1,896
+1,032
+119% +$8.18K ﹤0.01% 4952
2025
Q4 		$6.88K Sell
864
-579
-40% -$4.33K ﹤0.01% 5167
2025
Q3 		$9.91K Sell
1,443
-7,936
-85% -$43K ﹤0.01% 5025
2025
Q2 		$36.6K Sell
9,379
-7,386
-44% -$28.8K ﹤0.01% 4912
2025
Q1 		$63.5K Sell
16,765
-21,709
-56% -$124K ﹤0.01% 4810
2024
Q4 		$209K Buy
38,474
+16,377
+74% +$77.2K ﹤0.01% 4387
2024
Q3 		$92.6K Buy
+22,097
New +$81.6K ﹤0.01% 4793
2022
Q2 		– Sell
-273
Closed -$1K – 6314
2022
Q1 		$1K Buy
+273
New +$774 ﹤0.01% 6153

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup's DMAC Position: Q2 2026 in Review

Citigroup increased its DiaMedica Therapeutics (DMAC) stake by 811% in Q2 2026, buying an estimated $94.5K and bringing the position to 17,272 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #4575.

Citigroup first reported a position in DMAC in Q1 2022 and has held it in 9 quarters since. The position peaked at $209K in Q4 2024. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Citigroup held 17,272 shares of DiaMedica Therapeutics worth $122K as of Q2 2026.
  • Citigroup bought 15,376 DiaMedica Therapeutics shares in Q2 2026, an estimated $94.5K.
  • DiaMedica Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4575 holding.
  • Citigroup first reported a position in DiaMedica Therapeutics in Q1 2022 and has held it in 9 quarters since.
  • Citigroup's DiaMedica Therapeutics position peaked at $209K in Q4 2024.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.